UK to fund use of Keytruda combo in first-line cancer setting

26 July 2024

In the UK, the health technology assessor has ruled in favor of reimbursing a new use for Merck & Co’s (NYSE: MRK) Keytruda (pembrolizumab).

The decision covers use of the leading checkpoint blocker, together with chemotherapy, for the first line treatment of certain people with gastric or gastro-oesophageal junction adenocarcinoma.

Gastric cancer, the fifth most common cancer globally, sees over 6,500 new cases annually in the UK and often goes undetected until advanced stages.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK